Warf 2 mg (Warfarin) Malaria combination therapy Invokana is approved by regulatory

Invokana is approved by regulatory authorities such as the FDA for glycemic control in adults with type 2 diabetes

leading to an increase in the number of LDL receptors on the surface of liver cells

Pentasa Suppository contains mesalamine

It acts as a powerful GLP-1 receptor agonist designed to maximize appetite suppression

interrupting the viral lifecycle before it can cause cellular changes leading to cancer or warts

Warf 2 mg (Warfarin) Malaria combination therapy Invokana is approved by regulatoryProduct Overview Warf 2 mg is a prescription anticoagulant medication containing the active ingredient Warfarin, manufactured by Cipla Limited. It is supplied as 15 tablets per strip and is primarily indicated for the prevention and management of blood clots. Warfarin is widely utilized in clinical practice for its efficacy in reducing the risk of thromboembolic events. What is Warf 2 mg (Warfarin)? Warf 2 mg contains Warfarin, a vitamin K antagonist